Table 1

Clinical characteristics of included patients within each cohort at baseline

MetforminSulfonylureaThiazolidinedioneDPP4i
CPRD
 N13,82310,0709,0885,119
 Age (years)65.1 (10.8)64.0 (10.8)63.4 (10.4)64.1 (10.3)
 Female sex, n (%)5,351 (39)3,924 (39)3,398 (37)1,894 (37)
 Duration of diabetes (years)4.9 (4.0)5.2 (3.8)6.7 (4.8)7.8 (4.9)
 BMI (kg/m2)30.5 (5.7)a31.1 (6.0)b31.4 (6.0)c32.5 (6.1)d
 HbA1c (mmol/mol)70.5 (15.0)72.0 (15.5)72.0 (13.9)71.1 (13.6)
 HbA1c (%)8.6 (1.4)8.7 (1.4)8.7 (1.3)8.7 (1.2)
 Dose (% maximum dose)59.7 (19)e32.1 (16.7)f56.2 (18.4)g97.8 (10.3)h
 Weight change over 12 m (kg)−1.4 (4.0)i2.0 (4.5)j2.8 (4.5)k−0.9 (4.0)l
GoDARTS
 N927729677244
 Age (years)66.3 (10.2)65.3 (10.5)63.7 (9.8)65.3 (9.8)
 Female sex, n (%)41403943
 Duration of diabetes (years)5.3 (4.0)6.0 (3.7)8.4 (5.2)6.7 (4.6)
 BMI (kg/m2)31.4 (5.7)m31.6 (5.8)n32.1 (5.7)o32.9 (5.9)p
 HbA1c (mmol/mol)67.9 (13.4)70.2 (14.7)72.9 (13.0)70.5 (11.3)
 HbA1c (%)8.3 1.238.6 1.348.8 1.188.6 1.10
 Dose (% maximum dose)55 (18)q28 (16)r73 (41)s99.6 (0.1)t